Literature DB >> 3614305

Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin.

D L Hurley, R D Tiegs, H W Wahner, H Heath.   

Abstract

Whether calcitonin deficiency causes and calcitonin excess prevents bone loss is controversial. We therefore measured plasma calcitonin levels and bone mineral density at the radius (by single photon absorptiometry) and lumbar spine (dual photon absorptiometry) in patients with an excess or deficiency of calcitonin. We studied 21 patients who had undergone subtotal thyroidectomy 6.8 to 29 years previously and had no calcitonin secretory reserve, and 11 patients who had received a diagnosis of medullary thyroid carcinoma 6.8 to 23 years previously and had chronic hypercalcitoninemia. Bone-density values, expressed as Z-scores (i.e., as the number of standard deviations above or below the normal means adjusted for age and sex), were indistinguishable from normal in the patients who had undergone thyroidectomy (means +/- SE: radius, 0.36 +/- 0.15; spine, 0.27 +/- 0.17). In the patients with medullary thyroid cancer, radial bone-density values were normal (-0.26 +/- 0.39), but spinal density was significantly reduced (-0.75 +/- 0.17, P less than 0.01). There were no significant correlations between the duration of calcitonin excess or deficiency and the bone density at either site. Bone mineral density was not affected by whether or not thyroxine replacement therapy was given. We conclude that skeletal mass is not affected by endogenous plasma calcitonin in adults.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3614305     DOI: 10.1056/NEJM198708273170904

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  16 in total

1.  Calcitonin and estrogens.

Authors:  D Agnusdei; R Civitelli; A Camporeale; C Gennari
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

2.  Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients.

Authors:  P Schneider; P Berger; K Kruse; W Börner
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

Review 3.  Pathogenesis of osteoporosis.

Authors:  H K Väänänen
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

4.  The effect of high-dose salmon calcitonin on bone mineral metabolism in the normal rat.

Authors:  N Glajchen; S Thomas; P Jowell; S Epstein; F Ismail; M Fallon
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

5.  Calcitonin and bone mass status in congenital hypothyroidism.

Authors:  N Demeester-Mirkine; P Bergmann; J J Body; J Corvilain
Journal:  Calcif Tissue Int       Date:  1990-04       Impact factor: 4.333

6.  Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene.

Authors:  Ana O Hoff; Philip Catala-Lehnen; Pamela M Thomas; Matthias Priemel; Johannes M Rueger; Igor Nasonkin; Allan Bradley; Mark R Hughes; Nelson Ordonez; Gilbert J Cote; Michael Amling; Robert F Gagel
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

7.  Altered calcitonin gene in a young patient with osteoporosis.

Authors:  M Alevizaki; J C Stevenson; S I Girgis; I MacIntyre; S Legon
Journal:  BMJ       Date:  1989-05-06

8.  Calcitonin secretion rate in elderly normal subjects.

Authors:  M Pedrazzoni; G Ciotti; L Davoli; G Pioli; G Girasole; T Santini; M Michelini; P P Vescovi; M Passeri
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

9.  Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study.

Authors:  S Ljunghall; P Gärdsell; O Johnell; K Larsson; E Lindh; K Obrant; I Sernbo
Journal:  Calcif Tissue Int       Date:  1991-07       Impact factor: 4.333

10.  The long-term effect of a calcium diet on the bone tissue, C-cells and parathyroid glands of the rat.

Authors:  M Logonder-Mlinsek; Z Pajer
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.